A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 5, 2008, Pages 924-931

  Mitchell, Paul L R ^a   Marlton, Paula ^b   Grigg, Andrew ^c   Seymour, John ^d   Hertzberg, Mark ^e   Enno, Arno ^f   Herrmann, Richard ^g   Bond, Rodney ^h   Arthur, Chris ⁱ  

^a AUSTIN HOSPITAL   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f NEWCASTLE MATER HOSPITAL   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h ST JOHN OF GOD HOSPITAL   (Australia)

ⁱ ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

DaunoXome; Elderly; G CSF; Liposomal daunorubicin; Non Hodgkin lymphoma

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK POPULATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DAUNORUBICIN; HUMANS; INFECTION; LIPOSOMES; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 46749101385     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802007700     Document Type: Article

References (35)

1. Thieblemont, C. and Coiffier, B. (2007) Lymphoma in older patients. J Clin Oncol, 25, pp. 1916-1923.
2. Maartense, E., Hermans, J., Kluin-Nelemans, J. C., Kluin, P. M., Van Deijk, W. A. and Snijder, S. (1998) Elderly patients with non-Hodgkin's lymphoma: Population-based results in the Netherlands. Ann Oncol, 9, pp. 1219-1227.
3. Shipp, M. A. and On behalf of the International Non-Hodgkin's Lymphoma Prognostic Factors Group (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 329, pp. 987-994.
4. Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M. and Mize, E. M. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 328, pp. 1002-1006.
5. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. and Bouabdallah, R. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New Engl J Med, 346, pp. 235-242.
6. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R. and Ferme, C. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphomas: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 23, pp. 4117-4126.
7. Pfreundschuh, M., Trumper, L., Ma, D., Osterborg, A., Pettengell, R. and Trneny, M. (2004) Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab - early stopping after the first interim analysis. Proc ASCO, 22:14, p. 6500.
8. Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A. C. and Rube, C. (2004) 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood, 104, pp. 634-641.
9. Green, M. (1998) Anthracycline cardiotoxicity, no longer an issue?. Ann Oncol, 9, pp. 691-693.
10. Limat, S., Demesmay, K., Voillat, L., Bernard, Y., Deconinck, E. and Brion, A. (2003) Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol, 14, pp. 277-281.
11. Sonneveld, P., de Ridder, M., van der Lelie, H., Nieuwenhuis, K., Schouten, H. and Mulder, A. (1995) Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol, 13, pp. 2530-2539.
12. Meyer, R. M., Browman, G. P., Samosh, M. L., Benger, A. M., Bryant-Lukosius, D. and Wilson, W. E. (1995) Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol, 13, pp. 2386-2393.
13. Sadava, D., Coleman, A. and Kane, S. E. (2002) Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res, 12, pp. 301-309.
14. Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M. and von Roenn, J. H. (1996) Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol, 14, pp. 2353-2364.
15. Rosenthal, E., Poizot-Martin, I., Saint-Marc, T., Spano, J. P. and Cacoub, P. (2002) Phase IV study of liposomal daunorubicin (daunoxome) in AIDS-related Kaposi's sarcoma. Am J Clin Oncol, 25, pp. 57-59.
16. Richardson, D. S., Kelsey, S. M., Johnson, S. A., Tighe, M., Cavenagh, J. D. and Newland, A. C. (1997) Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs, 15, pp. 247-253.
17. Flinn, I. W., Goodman, S. N., Post, L., Jamison, J., Miller, C. B. and Gore, S. (2000) A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL. Ann Oncol, 11, pp. 691-695.
18. McBride, N. C., Cavenagh, J. D., Ward, M. C., Grant, I., Schey, S. and Gray, A. (2001) Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkin's lymphoma. Leuk Lymphoma, 42, pp. 89-98.
19. Tulpule, A., Rarick, M. U., Kolitz, J., Bernstein, J., Myers, A. and Buchanan, L. A. (2001) Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol, 12, pp. 457-462.
20. Tsimberidou, A. M., Kantarjian, H. M., Cortes, J., Thomas, D. A., Faderl, S. and Garcia-Manero, G. (2003) Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony-stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer, 97, pp. 1711-1720.
21. Mohrbacher, A. F., Gregory, S. A., Gabriel, D. A., Rusk, J. M. and Giles, F. J. (2002) Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study. Cancer, 94, pp. 2645-2652.
22. Guaglianone, P., Chan, K., DelaFlor-Weiss, E., Hanisch, R., Jeffers, S. and Sharma, D. (1994) Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs, 12, pp. 103-110.
23. O'Byrne, K. J., Thomas, A. L. and Sharma, R. A. (2002) A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer, 87, pp. 15-20.
24. Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K. and Cleary, M. L. (1994) A revised European-American classification of lymphoid malignancies: A proposal from the International Lymphoma Study Group. Blood, 84, p. 1361.
25. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for Non-Hodgkin's Lymphomas. J Clin Oncol, 17, pp. 1244-1253.
26. Armitage, J. O. and Potter, J. F. (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age. J Am Geriatr Soc, 32, pp. 269-273.
27. Bastion, Y., Blay, J. Y., Divine, M., Brice, P., Bordessoule, D. and Sebban, C. (1997) Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment and survival - a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol, 15, pp. 2945-2953.
28. Havlik, R. J., Yancik, R., Long, S., Ries, L. and Edwards, B. (1994) The National Institute on Ageing and the National Cancer Institute SEER collaborative study on co-morbidity and early diagnosis of cancer in the elderly. Cancer, 74, pp. 2101-2106.
29. Dixon, D. O., Neilan, B., Jones, S. E., Lipschitz, D. A., Miller, T. P. and Grozea, P. N. (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol, 4, pp. 295-305.
30. Lipshutz, S., Colan, S., Gelber, R., Perez-atayde, A. R., Sallan, S. E. and Sanders, S. P. (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med, 324, pp. 808-815.
31. Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J. and Guthrie, T. (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. J Clin Oncol, 19, pp. 1444-1454.
32. Grillo-Lopez, A. J., Cheson, B. D., Horning, S. J., Peterson, B. A., Carter, W. D. and Varns, C. L. (2000) Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. Ann Oncol, 11, pp. 399-408.
33. Martino, R., Perea, G., Caballero, M. D., Mateos, M. V., Ribera, J. M. and de Oteyza, J. P. (2002) Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisolone (CCOP) in elderly patients with diffuse large-cell lymphoma: Results of a prospective phase II study. Haematologica, 87, pp. 822-827.
34. Aviles, A., Neri, N., Castaneda, C., Talavera, A., Huerta-Guzman, J. and Gonzalez, M. (2002) Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-cell lymphoma. Med Oncol, 19, pp. 55-58.
35. Zaja, F., Tomadini, V., Zaccaria, A., Lenoci, M., Battista, M. and Molinari, A. L. (2006) CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large cell lymphoma. Leuk Lymphoma, 47, pp. 2174-2180.